FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an antibody specifically binding to a protein containing triple helix repeats of collagen-1 CTHRC1. Also disclosed is a polynucleotide coding said antibody; an expression vector comprising said vector; host cell containing said vector; composition or kit containing said antibody. Disclosed is a method of providing information for diagnosing or predicting a malignant disease; method of determining protein CTHRC1 in a sample.
EFFECT: invention has the ability to effectively treat a malignant disease with high expression of CTHRC1.
15 cl, 22 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES DIRECTED TO CD127 | 2015 |
|
RU2734076C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| COMPOSITION FOR TREATING CANCER, COMBINING ANTI-CD26 ANTIBODY AND OTHER ANTI-CANCER AGENT | 2016 |
|
RU2742953C2 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO CONSTANT REGION OF β T-CELL RECEPTOR | 2015 |
|
RU2830064C2 |
| TIGIT ANTIBODIES AND USE THEREOF | 2020 |
|
RU2827445C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
